Pcn423 Measuring Fatigue Symptoms and Impacts in Chronic Lymphocytic Leukemia (Cll): Evaluating Dimensionality of the Facit-Fatigue

Abstract

7.15 and 7.36 years, in the 18-and 30-month DBLs, respectively. Extrapolated 18-month DBL landmark survival at 5, 10, and 20 years was 39.9%, 23.0%, and 11.1%, which remained stable at the 30-month DBL as 40.7%, 23.9%, and 11.8%, all respectively. Conclusions: Nivolumab+ipilimumab is the first immunooncology combination that has shown significant and stable long-term OS benefit in 1L RCC compared with standard of care (sunitinib). The new DBLs confirm the robustness of the 18-month DBL results, including the choice of a log-normal distribution for extrapolation.